

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILI	NG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/085,072 03/01/2002		/01/2002	Bozidar Ferek-Petric	P-8158.02 DIV1	1422	
27581	7590	08/09/2005		EXAMINER		
MEDTRONIC, INC.				OROPEZA, I	OROPEZA, FRANCES P	
710 MEDTR	ONIC PAR	KWAY NE				
MS-LC340				ART UNIT	PAPER NUMBER	
MINNEAPOLIS, MN 55432-5604				3762		

DATE MAILED: 08/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Ар	plication No.	Applicant(s)					
)/085,072	FEREK-PETRIC,	BOZIDAR				
Office A	Action Summary	Ex	aminer	Art Unit					
		Fra	ances P. Oropeza	3762					
The MAILIN Period for Reply	G DATE of this commun	ication appears	on the cover sheet with the c	orrespondence ad	dress				
A SHORTENED S THE MAILING DA - Extensions of time may after SIX (6) MONTHS f - If the period for reply sp - If NO period for reply is - Failure to reply within th Any reply received by th	TE OF THIS COMMUNI be available under the provisions from the mailing date of this comm ecified above is less than thirty (3) specified above, the maximum sta e set or extended period for reply	CATION. of 37 CFR 1.136(a). unication. d) days, a reply withinatutory period will app will, by statute, cause	SET TO EXPIRE 3 MONTH(In no event, however, may a reply be timenthe statutory minimum of thirty (30) days only and will expire SIX (6) MONTHS from the application to become ABANDONE of this communication, even if timely filed	nely filed s will be considered timely the mailing date of this co D (35 U.S.C. § 133).					
Status									
1) Responsive	to communication(s) file	d on <u>6/22/05 (/</u>	RCE) & 5/23/05 (Amendment	<u>0</u> .					
2a) This action is	2a) This action is FINAL . 2b) ⊠ This action is non-final.								
•	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims	S								
4a) Of the ab 5) ☐ Claim(s) 6) ☑ Claim(s) <u>35-</u> 7) ☐ Claim(s)	39 and 43-47 is/are pen ove claim(s) is/are is/are allowed. 39 and 43-47 is/are reje is/are objected to are subject to restrice.	re withdrawn fr	om consideration.						
Application Papers									
9)☐ The specifica	tion is objected to by the	e Examiner.							
10) The drawing(s) filed on is/are:	a) accepted	d or b) \square objected to by the E	Examiner.					
Applicant may	not request that any object	ction to the draw	ing(s) be held in abeyance. See	37 CFR 1.85(a).					
<u> </u>	* '		required if the drawing(s) is obj ner. Note the attached Office		` '				
Priority under 35 U.S.	.C. § 119								
a) All b) S 1. Certifie 2. Certifie 3. Copies applica	Some * c) None of: ed copies of the priority of ed copies of the priority of s of the certified copies of ation from the Internation	documents hav documents hav of the priority d nal Bureau (PC	ve been received in Application ocuments have been received	on No d in this National	Stage				
Attachment(s)			" □						
Notice of References Notice of Draftspersor	Cited (PTO-892) a's Patent Drawing Review (P	TO-948)	4)						
	Statement(s) (PTO-1449 or I		5) Notice of Informal Pa		I-152)				

Application/Control Number: 10/085,072 Page 2

Art Unit: 3762

DETAILED ACTION

Request for Continued Examination

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. The Applicant's submission filed on 6/22/05 has been entered.

Declaration

2. The evidence submitted is insufficient to establish a reduction to practice of the invention in this country or a NAFTA or WTO member country prior to the effective date of the Soyken et al. reference (US 6206914). In the declaration, the Applicant swears invention prior to August 1998, but the priority date to the Soykan et al. reference is April 30 1998.

Claim Rejections - 35 USC § 112

- 3. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 4. Claim 38 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The

Application/Control Number: 10/085,072

Art Unit: 3762

Examiner is unable to find a programmer means for "controlling" the signal processor means in the original specification. New matter may not be added at this point in the prosecution.

Appropriate correction is required.

Claim Rejections - 35 USC § 102

Claims 35-38 and 43-47 are rejected under 35 U.S.C. 102(b) as being anticipated by Soykan et al. (US 6206914). Soykan et al. teach an implantable system with drug treatment that monitors ECG signals and coronary sinus blood flow signals to detect and treat ischemia (fig. 5; col. 1 @ 23-39; col. 2 @ 30-40; col. 3 @ 23-30; col. 4 @ 18-23; col. 5 @ 21-36; col. 13 @ 46-64; col. 16 @ 23-46). Soykan et al. teach modify and incorporating the stimulation device of US 5702427 to Ecker et al. (col. 16 @ 53-58), hence including atrial and ventricular sensing means and signals in the instant invention (fig. 9). The sensing elements monitors changes in the circulatory system, inherently occurring over a period of time, where a reduction of blood flow, read to be about a 25% decrease in blood flow, can be indicated by changes in the ST segment (col. 5 @ 21-28).

Specification

7. The amendment filed 5/23/05 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: in claim 38 the limitation in quotations, a programmer means for "controlling" the signal processor means.

Art Unit: 3762

Applicant is required to cancel the new matter in the reply to this Office Action.

8. The specification is objected to as failing to provide proper antecedent basis for the claimed subject matter. See 37 CFR 1.75(d)(1) and MPEP § 608.01(o). Correction of the following is required: Original claim 38, "programmer means for enabling the signal processing means".

Statutory Basis

9. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fran Oropeza whose telephone number is (571) 272-4953.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert E. Pezzuto can be reached on (571) 272-6996. The fax phone numbers for the organization where this application or proceeding is assigned is (571) 273-8300 for regular communication and for After Final communications.

Frances P. Oropeza Patent Examiner Art Unit 3762 Robert E. Pezzuto

Supervisory Patent Examiner

Art Unit 3762